Blue Cross Blue Shield/Blue Care Network of Michigan
Medication Authorization Request Form

Blue Cross Blue Shield Blue Care Network of Michigan

Nonprofit corporations and independent licensees of the Blue Cross and Blue Shield Association

This form is to be used by participating physicians to obtain coverage for **drugs covered under the medical benefit**. For commercial members only, please complete this form and submit via fax to 1-877-325-5979. If you have any questions regarding this process, please contact BCBSM Provider Relations and Servicing or the Medical Drug Helpdesk at 1-800-437-3803 for assistance.

PATIENT INFORMATION		PHYSICIAN INFORMATION
Name		**Name**
ID Number		**Specialty**
D.O.B.	_____/_____/_____ MM/DD/YYYY ❑Male ❑Female	**Address**
Diagnosis		**City /State/Zip**
Drug Name	**BENLYSTA**	**Phone:** **Fax:**
Dose and Quantity		**NPI**
Directions		**Contact Person**
Date of Service(s)		**Contact Person** **Phone / Ext.**

STEP 1: DISEASE STATE INFORMATION

Required Demographic Information:

Patient Weight: _____*kg*

Patient Height: _____ft _____inches

Will the provider be administering the medication to the FEP member within the health plan's geographic service area?

❑ Yes ❑ No *If No, a prior authorization is not required through this process*.

Prior authorizations are required for FEP members that will be serviced by a provider within the health plan's geographic service area. If you are not a provider in the geographic service area, please contact the health plan for questions regarding the FEP member's benefit requirements.

Is this member's FEP coverage primary or secondary coverage?

❑ If primary, continue with questionset.

❑ If secondary, **an authorization is not needed through this process. Please contact the member's primary coverage for determination of benefit and additional information.**

Site of Care:

A. At what location will the member be receiving the requested medication?

❑ Physician's office, home infusion, non-hospital affiliated ambulatory infusion center.

❑ Outpatient hospital infusion center. Please provide the name of the infusion center and rationale why the patient must receive this medication in a hospital outpatient setting. _____

_____

❑ Other. Please specify. _____

Criteria Questions:

1. What is the patient's diagnosis?

❑ Lupus nephritis

a. **Patient 5-17 Years of Age**: Will the patient be receiving Benlysta as intravenous infusion (IV)? ❑Yes ❑No

b. Is the patient receiving standard therapy (e.g., corticosteroids, cyclosporine, tacrolimus, cyclophosphamide, azathioprine, mycophenolate, and rituximab)? ❑Yes ❑No

c. Has the patient been on Benlysta continuously for the last **4 months**, excluding samples? ***Please select answer below:***

❑ **NO** – this is **INITIATION** of therapy, please answer the following question:

i. Is the patient's lupus nephritis active? ❑Yes ❑No

❑ **YES** – this is a PA renewal for **CONTINUATION** of therapy, please answer the following question:

i. Does the patient have a documented clinical benefit from therapy (i.e., decrease or stabilization of symptoms, improvement in functional impairment, decrease of corticosteroid dose, decrease in pain medications, decrease in the number of exacerbations since prior to the start of Benlysta)? ❑Yes ❑No

❑ Systemic Lupus Erythematosus (SLE)

a. **Patient 5-17 Years of Age**: Will the patient be receiving Benlysta as intravenous infusion (IV)? ❑Yes ❑No

b. Is the patient receiving standard therapy [e.g., corticosteroids, NSAID, azathioprine, leflunomide, methotrexate, mycophenolate, tacrolimus, and antimalarial (e.g., hydroxychloroquine, chloroquine, quinine, quinidine, mefloquine)]? ❑Yes ❑No

c. Has the patient been on Benlysta continuously for the last **4 months**, excluding samples? ***Please select answer below:***

❑ **NO** – this is **INITIATION** of therapy, please answer the following questions:

i. Is the patient's systemic lupus erythematosus (SLE) active? ❑Yes ❑No

ii. Is the patient autoantibody-positive? ❑Yes ❑No

❑ **YES** – this is a PA renewal for **CONTINUATION** of therapy, please answer the following question:

i. Does the patient have a documented clinical benefit from therapy (e.g., improvement in functional impairment, decrease of corticosteroid dose, decrease in pain medications, decrease in the number of exacerbations since prior to the start of Benlysta)? ❑Yes ❑No

❑ Other diagnosis ***(please specify):*** _____

2. Does the prescriber agree to review and discuss with Black/African American patients the limited evidence of benefit of Benlysta in this population compared to standard treatment? ❑Yes ❑No ❑Patient is not Black/African American

3. Does the patient have a chronic infection, including, but not limited to Hepatitis B, Hepatitis C, HIV, or TB? ❑Yes ❑No

4. Does the patient have severe active central nervous system lupus? ❑Yes ❑No

5. Will the patient be given live vaccines while on Benlysta? ❑Yes ❑No

6. Does the patient concurrently take Benlysta with a biologic medication? ❑Yes* ❑No
If YES, specify medication: _____

Chart notes are required for the processing of all requests. Please add any other supporting medical information necessary for our review **(required)**

Coverage will not be provided if the prescribing physician's signature and date are not reflected on this document.

❑ Request for expedited review: I certify that applying the standard review time frame may seriously jeopardize the life or health of the member or the member's ability to regain maximum function

Physician's Name	**Physician Signature**	**Date**
Step 2: Checklist	❑ Form Completely Filled Out ❑ Provide chart notes	❑ Attach test results
Step 3: Submit	**By Fax: BCBSM Specialty Pharmacy Mailbox 1-877-325-5979**	**By Mail: BCBSM Specialty Pharmacy Program P.O. Box 312320, Detroit, MI 48231-2320**